Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Stiefel and Allergan enter into dermatologic collaboration

Stiefel and Allergan enter into dermatologic collaboration

7th November 2007

Stiefel Laboratories and Allergan have announced the start of a strategic collaboration that will see the two companies develop, manufacture, distribute and promote dermatological products containing tazarotene.

Under the agreement, Allergan has offered its proprietary technology and tazarotene to Stiefel with Stiefel then providing its US sales force to co-promote Allergan’s Tazorac to dermatologists.

Stiefel will also build on its existing patent protected technology and Allergan’s tazarotene compound to develop new therapeutic options to market for common dermatological diseases.

Bill Humphries, chief commercial officer at Stiefel, described the collaboration as a “great opportunity”.

“Given our long-standing and well-established presence in the dermatology arena, we will be able to make an immediate and important impact with Tazorac,” he confirmed.

Allergan’s corporate vice-president Julian Gangolli echoed Mr Humphries delight with the agreement, insisting that it would further strengthen the companies’ presence in the medical dermatology market.

He went on to illustrate that Tazorac was already a well recognised brand with dermatologists but that with Stiefel’s “experience, expertise and capabilities”, Allergan would be able to effectively develop and market new products involving tazarotene.

Last month Stiefel announced the appointment of Jim Loerop to the position of senior vice-president of global corporate development at the firm.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.